Why Valeant Pharmaceuticals Intl Inc. Shares Surged as Much as 17% on Monday

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares soared after the company announced Michael Pearson will be stepping down.

| More on:
The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On March 21, there were more developments in the Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) saga.

Most notably, the company announced that CEO Michael Pearson will be stepping down as soon as a successor is found. In addition, activist investor Bill Ackman, head of Pershing Square Capital Management, has now joined the board of directors. And to top it all off, Valeant blamed its past financial misstatements on former CFO Howard Schiller and asked him to resign from the board of directors. Yet he has refused to do so.

While these developments may look like signs of chaos, investors reacted warmly to the news, sending Valeant’s shares up by as much as 17%. So why exactly did Valeant’s shares increase, and what does this news mean for the company in the long term?

Michael Pearson’s departure

Michael Pearson has been the face of Valeant’s rise as well as its fall. It was he who moved the company from the United States to Canada primarily for tax reasons. It was he who slashed Valeant’s R&D spending in favour of an acquisition-based model. And as the company finds itself in a downward spiral, he is at the centre of it all.

Up until March he was still held in very high regard. When the Philidor story dominated headlines, Mr. Ackman reiterated his support for Mr. Pearson. Then when Mr. Pearson had to step down at the end of 2015 (for health-related reasons), Valeant’s share price fell. More recently, Nomura Securities analyst Shibani Malhotra said Valeant would lose its competitive advantage if Mr. Pearson stepped down.

But that all changed when Valeant lowered its 2016 guidance on March 14. Now there’s a sense that the company has no idea what it’s doing, which, of course, reflects badly on the CEO. So it’s no surprise that his departure is being received well.

Bill Ackman’s presence

Not unlike Mr. Pearson, Bill Ackman is another public figure whose reputation has taken a dramatic turn for the worse.

Long known as one of Wall Street’s best activist investors, Mr. Ackman has had some remarkable successes; for example, he initiated the turnaround at Canadian Pacific Railway Limited, which has been a tremendous win for shareholders of that company.

But more recently, the story has been very different. When Valeant started running into trouble, he increased his stake, saying his biggest regret was that he wasn’t in a position to buy more shares. He also said that the company’s biggest problem was poor communication. During a conference call, he even predicted that Valeant’s shares would reach US$448 by 2019.

Yet Mr. Ackman still is held in high regard, so his decision to join the board may be viewed as a small positive.

Howard Schiller

It may seem unfair that Mr. Schiller is being made the scapegoat, since he stepped in as interim-CEO during a very difficult time. Then again, he was CFO at a time when the company misstated its financials.

In any case, this controversy is really more of a side story. Mr. Pearson’s departure was certainly the main reason Valeant’s share price increased, and Mr. Ackman’s increased involvement was likely a factor as well. We’ll have to wait and see how this all plays out.

Should you invest $1,000 in Bausch Health Companies right now?

Before you buy stock in Bausch Health Companies, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Bausch Health Companies wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

ways to boost income
Dividend Stocks

How I’d Invest $5,000 in Canadian Energy Stocks to Reach Toward Millionaire Status

These energy stocks can provide investors in Canada with some of the top growth opportunities and dividends to boot!

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Tuesday, April 29

With election results in and earnings season heating up, several factors could sway TSX stocks in today’s session.

Read more »

senior relaxes in hammock with e-book
Dividend Stocks

How I’d Invest $8,200 in Canadian Monthly Dividend Stocks to Pay for My Retirement Lifestyle

If you have some cash on hand, then these monthly dividend stocks can provide you with cash for life.

Read more »

protect, safe, trust
Investing

Protecting a $5,000 Investment: Why I’m Considering These 3 Defensive Stocks

These three top Canadian value stocks look well-positioned to provide portfolio stability and long-term upside for those navigating market turmoil.

Read more »

Canada national flag waving in wind on clear day
Investing

Where I’d Find Value in Canadian Stocks for My Long-Term Holdings

For investors seeking meaningful value (and long-term upside) from top Canadian stocks, here are two great examples to dive into…

Read more »

Circuit board with glowing lines
Tech Stocks

Got $1,500? How I’d Allocate it Between 2 Tech Stocks for Decades of Potential Growth

Are you looking to put $1,500 to work? These two Canadian tech stocks are a great place to start.

Read more »

man is enthralled with a movie in a theater
Investing

Is Now a Good Time to Buy Cineplex?

The decision of whether it's a good time to buy Cineplex has confounded investors since the pandemic, but It may…

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Investing

Why I’d Consider These 3 TSX Stocks Under $100 for my $7,000 TFSA Contribution

Here are three top TSX stocks I think long-term investors would do well to own in their TFSAs during this…

Read more »